This was the stock's third consecutive day of losses.

Fintel reports that on March 5, 2025, Citigroup upgraded their outlook for ResMed Inc. - Depositary Receipt () (OTCPK:RSMDF) ...

Fintel reports that on March 5, 2025, Citigroup upgraded their outlook for ResMed (NYSE:RMD) from Neutral to Buy. Analyst ...

Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fifteen research ...

Citi upgraded ResMed (RMD) to Buy from Neutral with a price target of A$44, up from A$41. The firm likes the stock’s “reasonable valuation, ...

ResMed has been in a holding pattern, posting a small loss of 4.8% while floating around $233.10. The stock also fell short ...

Shares in health groups Cochlear and Integral Diagnostics rallied after Citi upgraded its ratings on both stocks to 'buy'.

Shares of ResMed Inc. RMD shed 1.42% to $231.28 Thursday, on what proved to be an all-around poor trading session for the ...

These include a sustainable business model, a long track of profitability, rising cash flows, good liquidity, a strong balance sheet and some value characteristics. A history of strong dividend growth ...

Over 70% of Indian couples opt for sleep divorce to improve rest, citing snoring, stress, and mismatched schedules - ...